hSSB1在口腔鳞状细胞癌中的表达及临床意义

doi:10.13591/j.cnki.kqyx.2026.02.007

摘要/Abstract

摘要：

目的探讨人单链DNA结合蛋白1(human single-stranded DNA-binding protein 1, hSSB1)在口腔鳞状细胞癌中的表达及作用。方法收集2022年1月至2023年12月在桂林医学院附属医院口腔颌面外科住院部收治的口腔鳞状细胞癌患者30例,通过免疫组化、Western blot及RT-qPCR方法检测癌组织与癌旁正常组织中hSSB1的表达情况,分析与临床参数的关系。结果 hSSB1蛋白与mRNA在口腔鳞状细胞癌组织中的表达水平均显著高于癌旁正常组织(P<0.05)。hSSB1的mRNA表达与临床参数无明显关系(P>0.05),hSSB1的蛋白表达与年龄、有无淋巴结转移、临床分期有关(P<0.05)。结论 hSSB1在口腔鳞状细胞癌中表达显著升高,可能参与了口腔鳞状细胞癌的发生发展过程。

关键词: hSSB1, DNA损伤修复, 口腔鳞状细胞癌, 发病机制

Abstract:

Objective To investigate the expression and clinical significance of human single-stranded DNA-binding protein 1 (hSSB1) in oral squamous cell carcinoma(OSCC). Methods A total of 30 OSCC patients treated at the Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Guilin Medical University between January 2022 and December 2023 were included. The expression levels of hSSB1 in OSCC tissues and adjacent normal tissues were detected using immunohistochemistry (IHC), Western blot, and RT-qPCR. The correlation between hSSB1 expression and clinicopathological features was analyzed. Results Both protein and mRNA expression levels of hSSB1 were significantly elevated in OSCC tissues compared with adjacent normal tissues (P<0.05). While hSSB1 mRNA expression was not significantly associated with any clinicopathological parameters (P>0.05), hSSB1 protein expression showed significant correlations with age, lymph node metastasis, and clinical stage (P<0.05). Conclusion hSSB1 is significantly up-regulated in OSCC and may play a role in the development and progression of the disease.

Key words: hSSB1, repair of DNA damage, oral squamous cell carcinoma, pathogenesis

中图分类号:

R739.86

曾祥林, 刘基沐, 覃小荣, 李波. hSSB1在口腔鳞状细胞癌中的表达及临床意义[J]. 口腔医学, 2026, 46(2): 126-130.

ZENG Xianglin, LIU Jimu, QIN Xiaorong, LI Bo. Expression and clinical significance of hSSB1 in oral squamous cell carcinoma[J]. Stomatology, 2026, 46(2): 126-130.

图/表 5

表1

图1

图2

表2

图3

参考文献 26

[1]	Tan YH, Wang ZH, Xu MT, et al. Oral squamous cell carcinomas: State of the field and emerging directions[J]. Int J Oral Sci, 2023, 15(1): 44. doi: 10.1038/s41368-023-00249-w pmid: 37736748
[2]	Chen DG, Zhang XM, Li ZJ, et al. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macroph-ages[J]. Theranostics, 2021, 11(3): 1016-1030.
[3]	Saikishore R, Velmurugan P, Ranjithkumar D, et al. The circular RNA-miRNA axis: A special RNA signature regulatory transcriptome as a potential biomarker for OSCC[J]. Mol Ther Nucleic Acids, 2020, 22: 352-361. doi: 10.1016/j.omtn.2020.09.001
[4]	Gou QT, Zheng LL, Huang HX. Unravelling the roles of autophagy in OSCC: A renewed perspective from mechanisms to potential applications[J]. Front Pharmacol, 2022, 13: 994643. doi: 10.3389/fphar.2022.994643
[5]	Pignatelli P, Romei FM, Bondi D, et al. Microbiota and oral cancer as a complex and dynamic microenvironment: A narrative review from etiology to prognosis[J]. Int J Mol Sci, 2022, 23(15): 8323. doi: 10.3390/ijms23158323
[6]	Kordbacheh F, Farah CS. Current andemerging molecular therapies for head and neck squamous cell carcinoma[J]. Cancers, 2021, 13(21): 5471. doi: 10.3390/cancers13215471
[7]	Ravindran S, Ranganathan S, Karthikeyan R, et al. The role of molecular biomarkers in the diagnosis, prognosis, and treatment str.PNGication of oral squamous cell carcinoma: A comprehensive review[J]. J Liq Biopsy, 2025, 7: 100285. doi: 10.1016/j.jlb.2025.100285
[8]	Richard DJ, Bolderson E, Cubeddu L, et al. Single-stranded DNA-binding protein hSSB1 is critical for genomic stability[J]. Nature, 2008, 453(7195): 677-681. doi: 10.1038/nature06883
[9]	Jiang HL, Sun HF, Gao SP, et al. SSBP1 suppresses TGFβ-driven epithelial-to-mesenchymal transition and metastasis in triple-negative breast cancer by regulating mitochondrial retrograde signaling[J]. Cancer Res, 2016, 76(4): 952-964.
[10]	Wu YZ, Chen HX, Lu JP, et al. Acetylation-dependent function of human single-stranded DNA binding protein 1[J]. Nucleic Acids Res, 2015, 43(16): 7878-7887. doi: 10.1093/nar/gkv707 pmid: 26170237
[11]	Peng H, Cai SL, Chen RC, et al. NABP2 as an oncogenic biomarker promotes hepatocellular carcinoma progression and metastasis[J]. Am J Transl Res, 2023, 15(6): 4203-4227. pmid: 37434816
[12]	Li BW, Liu JH, Xu LZ, et al. Comprehensive analysis of NABP2 as a prognostic biomarker and its correlation with immune infiltration in hepatocellular carcinoma[J]. J Inflamm Res, 2023, 16: 1783-1804. doi: 10.2147/JIR.S403370 pmid: 37113629
[13]	Huang J, Xie ZF. IdePNGication of SSBP1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches[J]. Math Biosci Eng, 2022, 19(3): 3022-3035. doi: 10.3934/mbe.2022139 pmid: 35240818
[14]	Adams MN, Croft LV, Urquhart A, et al. hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer[J]. Prostate, 2023, 83(7): 628-640. doi: 10.1002/pros.24496 pmid: 36811381
[15]	Nikolaev A, Yang ES. Theimpact of DNA repair pathways in cancer biology and therapy[J]. Cancers, 2017, 9(9): 126. doi: 10.3390/cancers9090126
[16]	Croft LV, Bolderson E, Adams MN, et al. Human single-stranded DNA binding protein 1 (hSSB1, OBFC2B), a critical component of the DNA damage response[J]. Semin Cell Dev Biol, 2019, 86: 121-128. doi: S1084-9521(17)30433-0 pmid: 29577982
[17]	Lawson T, El-Kamand S, Kariawasam R, et al. A structural perspective on the regulation of human single-stranded DNA binding protein 1 (hSSB1, OBFC2B) function in DNA repair[J]. Comput Struct Biotechnol J, 2019, 17: 441-446. doi: 10.1016/j.csbj.2019.03.014
[18]	Zhou LW, Zheng LS, Hu KS, et al. SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites[J]. Signal Transduct Target Ther, 2020, 5(1): 80.
[19]	El-Kamand S, Adams MN, Matthews JM, et al. The molecular details of a novel phosphorylation-dependent interaction between MRN and the SOSS complex[J]. Protein Sci, 2023, 32(10): e4782. doi: 10.1002/pro.4782 pmid: 37705456
[20]	Wang X, Wang YT, Zeng XL, et al. The single-strand DNA-binding protein SSB1 is involved in the expression of salivary gland radiation injury repair[J]. Front Pharmacol, 2024, 15: 1471996. doi: 10.3389/fphar.2024.1471996
[21]	Gao LJ, Lv QL, Huang YD, et al. Effect of silencing SSB1 gene on the expression of NBS1 in irradiated rat submandibular gland cells[J]. Cell Mol Biol (Noisy-le-grand), 2024, 70(1): 110-118. doi: 10.14715/cmb/2024.70.1.15 pmid: 38372104
[22]	Lindemann A, Takahashi H, Patel AA, et al. Targeting the DNA damage response in OSCC with TP53 mutations[J]. J Dent Res, 2018, 97(6): 635-644. doi: 10.1177/0022034518759068 pmid: 29489434
[23]	Lin MX, Wang J, Yao XW. Association between decreased p53 expression, elevated serum CagA levels, and oral squamous cell carcinoma[J]. Clinics (Sao Paulo), 2025, 80: 100632. doi: 10.1016/j.clinsp.2025.100632
[24]	Xu SB, Wu YZ, Chen Q, et al. hSSB1 regulates both the stability and the transcriptional activity of p53[J]. Cell Res, 2013, 23(3): 423-435. doi: 10.1038/cr.2012.162 pmid: 23184057
[25]	Lim AM, Young RJ, Collins M, et al. Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma[J]. Oral Oncol, 2012, 48(8): 698-702. doi: 10.1016/j.oraloncology.2012.02.014 pmid: 22410096
[26]	Schuurs ZP, Martyn AP, Soltau CP, et al. An exploration of small molecules that bind human single-stranded DNA binding protein 1[J]. Biology, 2023, 12(11): 1405. doi: 10.3390/biology12111405

基因	引物序列	扩增长度/bp
hSSB1	上游引物 5'-ACATTATCCGGCTCACCAAAG-3'	135
hSSB1	下游引物 5'-GCTCACTGAAGTTAGGAACCTCA-3'	135
β-actin	上游引物 5'-CATGTACGTTGCTATCCAGGC-3'	250
β-actin	下游引物 5'-CTCCTTAATGTCACGCACGAT-3'	250

临床参数		n	mRNA	统计量	P	蛋白	统计量	P
性别	男	26	2.99±1.32	t=-0.088	0.930	0.89±0.08	t=-0.128	0.899
性别	女	4	3.05±1.84	t=-0.088	0.930	0.89±0.05	t=-0.128	0.899
年龄/岁	≤55	15	3.20±1.34	r=-0.082	0.666	0.91±0.06	r=-0.392	0.032
年龄/岁	>55	15	2.78±1.40	r=-0.082	0.666	0.87±0.08	r=-0.392	0.032
直径/cm	≤2	13	3.33±1.43	r=-0.243	0.195	0.89±0.07	r=-0.392	0.518
直径/cm	>2	17	2.74±1.29	r=-0.243	0.195	0.89±0.08	r=-0.392	0.518
病理分级	高分化	21	3.05±1.30	H=0.498	0.780	0.90±0.06	H=3.672	0.159
	高-中分化	5	3.11±1.46			0.91±0.11
	中-低分化	4	2.54±1.84			0.84±0.08
临床分期	Ⅰ	11	3.21±1.51	H=0.307	0.959	0.88±0.07	H=11.948	0.008
	Ⅱ	9	2.90±1.35			0.94±0.06
	Ⅲ	5	2.94±1.10			0.91±0.05
	Ⅳ	5	2.74±1.63			0.81±0.02
淋巴结转移	无	21	3.09±1.38	t=-0.596	0.556	0.91±0.07	t=-2.385	0.024
淋巴结转移	是	9	2.78±1.38	t=-0.596	0.556	0.85±0.06	t=-2.385	0.024